Despite
potency against a variety of cancers in preclinical systems,
melittin (MEL), a major peptide in bee venom, exhibits non-specific
toxicity, severe hemolytic activity, and poor pharmacological properties.
Therefore, its advancement in the clinical translation system has
been limited to early-stage trials. Herein, we report a biohybrid
involving a bottlebrush-architectured poly(ethylene glycol) (PEG)
and MEL. Termed pacMEL, the conjugate consists of a high-density PEG
arrangement, which provides MEL with steric inhibition against protein
access, while the high molecular weight of pacMEL substantially enhances
plasma pharmacokinetics with a ∼10-fold increase in the area
under the curve (AUC∞) compared to free MEL. pacMEL
also significantly reduces hepatic damage and unwanted innate immune
response and all but eliminated hemolytic activities of MEL. Importantly,
pacMEL passively accumulates at subcutaneously inoculated tumor sites
and exhibits stronger tumor-suppressive activity than molecular MEL.
Collectively, pacMEL makes MEL a safer and more appealing drug candidate.